Latest by Sean R. Hosein
Researchers tested a single injection of the antibody canakinumab in HIV-positive people taking antiretroviral therapy and found that the drug significantly reduced inflammation and did not cause harm, at least in the short term.
Researchers found that inflammation in the arteries of HIV-positive people was "modestly increased" and that the level of inflammation in the lymph nodes was generally higher than in the arteries.
Researchers have found that having an elevated level of a protein that is released into the blood of people during chronic inflammation was linked to an increased risk for subsequent serious health problems as well as diminished survival.
Chronic HIV infection is associated with relatively high levels of inflammation and a growing body of evidence suggests that inflammation may increase the risk for a range of health problems.
New research assesses the impact of chronic inflammation on major clinical events -- heart attack, stroke, cancer, other serious complications, and the risk of death.
A study of people with HIV and hepatitis C co-infection finds that limited access to food is associated with higher levels of HIV in the blood and 10% fewer CD4+ immune cells.
By 2035, three-quarters of HIV-positive people in Italy and the U.S. will be over the age of 50. Researchers are calling for "multidisciplinary patient management" and geriatric medicine training for doctors who care for people living with HIV.
An update on long-acting formulations of cabotegravir and rilpivirine, which are being tested in clinical trials.
Bictegravir, an emerging integrase inhibitor that is co-formulated with two other anti-HIV drugs, showed an efficacy similar to Tivicay (dolutegravir) in a phase III clinical trial.
A large regisitry-linked database of almost 450,000 people living with HIV in eight U.S. states and Puerto Rico reported significant reductions in the risk of many cancers over time.